德州好的羊羔疯病治疗方法泰安癫痫病专科医院在哪,山东治疗羊癫疯花多少钱,日照那看癫痫病看得好啊,烟台治疗小儿羊羔疯病方法,山东癫痫病儿童癫痫有几个,德州孩子为什么抽搐,淄博癫痫专家讲述癫痫的症状表现

BEIJING, Feb. 12 (Xinhua) -- The Chinese government has reiterated a strict ban on hepatitis B tests during pre-employment physical examinations as many companies reportedly violated rules to require hepatitis B tests for job applicants.In a statement released Saturday, the Ministry of Health said that no health institutions are allowed to provide hepatitis B checks as part of pre-employment physical tests regardless of whether the examinees provide consent or not.On Feb. 10, 2010, the Ministry of Health, the Ministry of Education and the Ministry of Human Resources and Social Security jointly issued a circular demanding the cancellation of the hepatitis B tests during the health checks for school enrollment and employment nationwide.However, according to a survey released this week, which was conducted by the non-profit Beijing Yirenping Center, some 61.1 percent of the 180 state-run companies surveyed included hepatitis B checks in their pre-employment physical examinations.More surprisingly, 63 companies said that they would never consider hepatitis B carriers for a job or were reluctant to hire such people.Yu Fangqiang, the principal of the Yirenping Center, said that such violations mainly resulted from light punishment for violations and some health institutions' desire for profits.According to the survey, employers would only be fined between thousands to tens of thousands of yuan if they lose their lawsuits for bias against hepatitis B carriers.Meanwhile, a worker will spend a lot of time, energy and money to file a lawsuit and collect evidence in order to win.Liu Xiaonan, an associate professor with the China University of Political Science and Law, called on the government to hammer out a particular law and set up a special committee to investigate discrimination cases in order to ensure the rights of workers.In the statement released Saturday, the health ministry also ordered a careful investigation of all cases of hepatitis B discrimination, and promised that violators would be exposed and punished in accordance with laws and regulations.Medical tests show that hepatitis B virus can only be transmitted from mother to child during childbirth or by contact with the blood or other body fluids of an infected person.

WASHINGTON, May 25 (Xinhua) -- The number of young adults in the United States with high blood pressure may be much higher than previously reported, according to a new study by researchers at the University of North Carolina (UNC) at Chapel Hill.Researchers analyzed data on more than 14,000 men and women between 24 and 32 years old in 2008 from the National Longitudinal Study of Adolescent Health, known as Add Health. They found 19 percent had elevated blood pressure, also referred to as hypertension. Only about half of the participants with elevated blood pressure had ever been told by a health-care provider that they had the condition."The findings are significant because they indicate that many young adults are at risk of developing heart disease, but are unaware that they have hypertension," said Quynh Nguyen, a doctoral student at UNC's Gillings School of Global Public Health and the study's lead author. Hypertension is a strong risk factor for stroke and coronary heart disease, the leading cause of death for adults in the United States.The findings were published this week in the journal Epidemiology.Kathleen Mullan Harris, Add Health's principal investigator and a co-author of the paper, said the findings were noteworthy because they were from the first nationally representative, field- based study of blood pressure to focus on young adults."The message is clear," said Harris. "Young adults and the medical professionals they visit shouldn't assume they're not old enough to have high blood pressure. This is a condition that leads to chronic illness, premature death and costly medical treatment."

LOS ANGELES, May 9 (Xinhua) -- Drinking alcohol may raise the likelihood among teenagers to spend more time on computers, a new study suggests.The study, conducted by researchers at Weill Cornell Medical College, was based on a survey of 264 teenagers, aged 13 to 17.Results showed that compared with teens who did not report drinking, those who drank alcohol in the last month used a computer more hours per week for non-school-related activities, including the use of social networking sites.Drinking was also linked to more frequent social networking and listening to and downloading music, according to the study published Monday in the on-line edition of the journal Addictive Behaviors.However, there was no demonstrated link between alcohol use and computer use for school work, neither there was strong link between video games and drinking or on-line shopping and drinking."While the specific factors linking teenage drinking and computer use are not yet established, it seems likely that adolescents are experimenting with drinking and activities on the Internet," said Dr. Epstein, assistant professor of public health at the college."In turn, exposure to on-line material such as alcohol advertising or alcohol-using peers on social networking sites could reinforce teens' drinking."Children are being exposed to computers and the Internet at younger ages. For this reason it's important that parents are actively involved in monitoring their children's computer usage, as well as alcohol use."Teenagers typically first experiment with alcohol at age 12 or 13, according to the study.Family risk factors include lax parental supervision and poor communication, family conflicts, inconsistent or harsh discipline and a family history of alcohol or drug abuse."According to a national study conducted by the Pew Internet and American Life Project, more than half of parents of teenagers had filters installed on the computers their child uses to block content parents find objectionable, yet many parents do not use any form of parental monitoring, particularly for older teens," Epstein said.

SAN FRANCISCO, March 20 (Xinhua) -- Boeing's 747-8 Intercontinental took to the sky for the first time on Sunday, a milestone for the U.S. aviation giant's latest and biggest passenger plane.Live webcast by Boeing showed that a 747-8 Intercontinental touched down at around 2:25 p.m. PST (2125 GMT) Sunday at the Boeing Field airport in Seattle in the U.S. states of Washington, after wrapping up the airplane's inaugural flight that lasted about four and half hours.During the test flight, the pilots did some system and function checks and everything went fine, according to the webcast.The new 747-8 Intercontinental can carry 467 passengers in a three-class configuration, said Boeing, which touted the new wide- body jet airliner as the only airplane in the 400-500 seat market.The Boeing 747-8 Intercontinental takes off on its maiden flight from Paine Field, in Everett, Washington, March 20, 2011. The 747-8 Intercontinental willseat 467 passengers, 51 more than the latest model of the classic 747, and burn less fuel while offering passengers more comfort, the U.S. planemaker says.Using 787-technology GEnx engines, the airplane will be quieter, produce lower emissions and achieve better fuel economy for airlines, Boeing said.The airplane also features a new wing design and an upgraded flight deck. Its interior incorporates features from the Boeing 787 Dreamliner including a new curved, upswept architecture that will give passengers a greater sense of space and comfort, while adding more room for personal belongings.Boeing has noted that compared with its predecessor, the 747- 400, the 747-8 Intercontinental provides 16 percent better fuel economy, 16 percent less carbon emissions per passenger and generates 30 percent smaller noise footprint, while carries 51 more passengers.Boeing in February said that Korean Air, VIP customers and launch customer Lufthansa have ordered a total of 33 747-8 passenger planes, with the first delivery scheduled for the fourth quarter of this year.It is reported that the 747-8 Intercontinental has a list price of about 317 million U.S. dollars.Earlier in March, Boeing announced that it has signed an agreement with Air China for the purchase of five 747-8 Intercontinental jetliners.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.